Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. (Q47823211)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2004

Language	Label	Description	Also known as
English	Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.	scientific article published in March 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

0 references

0 references

1 reference

based on heuristic

inferred from title

Angel M. Carcaboso

1

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Rosa Maria Hernandez

2

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Manuel-Elkin Patarroyo

object named as

Patarroyo ME

5

0 references

author name string

Igartua M

3

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Rosas JE

4

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Pedraz JL

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

22

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

11-12

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

1423-1432

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunisation of women with rubella (RA27-3) vaccine administered intranasally

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intranasal immunization against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Can needle-free administration of vaccines become the norm in global immunization?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Pathways and strategies for developing a malaria blood-stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Elevated plasma levels of IgE in Plasmodium falciparum-primed individuals reflect an increased ratio of IL-4 to interferon-gamma (IFN-gamma)-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Identifiers

10.1016/J.VACCINE.2003.10.020

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/15063565

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47823211&oldid=1669911679"